In addition to significant support to advance osteopathic medicine in Ohio, the Osteopathic Heritage Foundation supports, on a national level, biomedical research on pressing diseases and the endowment of research and training chairs at top-ranked colleges of osteopathic medicine in the United States.
Foundation support for the endowed chairs has leveraged additional federal, state and private funding for scientific research in diabetes, chronic disorders related to aging and neuromusculoskeletal diseases, among others.
Click here to learn about Foundation sponsored endowed chairs and related research at colleges of osteopathic medicine.
Brian C. Clark, PhD, Executive Director, Ohio Musculoskeletal and Neurological Institute (OMNI) and Associate Professor of Physiology in the Department of Biomedical Sciences
Osteopathic Heritage Foundation Harold E. Clybourne, D.O., Endowed Research Chair in the Heritage College of Osteopathic Medicine
Robert G. Nagele, Ph.D., Professor of Medicine at Rowan School of Osteopathic Medicine (photo by: Lori M. Nichols/South Jersey Times)
A research team, led by Dr. Robert Nagele at Rowan University School of Osteopathic Medicine, announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy. In a “proof of concept” study involving 236 subjects, the test demonstrated an overall accuracy, sensitivity and specificity rate of 100 percent in identifying subjects whose MCI was actually caused by an early stage of Alzheimer’s disease.
These findings could eventually lead to the development of a simple, inexpensive and relatively noninvasive way to diagnose this devastating disease in its earliest stages. "It is now generally believed that Alzheimer’s-related changes begin in the brain at least a decade before the emergence of telltale symptoms,” Nagele explained. “To the best of our knowledge, this is the first blood test using autoantibody biomarkers that can accurately detect Alzheimer’s at an early point in the course of the disease when treatments are more likely to be beneficial – that is, before too much brain devastation has occurred.”
This research was supported, in part, by the Osteopathic Heritage Foundation and the Michael J. Fox Foundation.